The Effect of Nexium on Transmucosal Esophageal Leak
Status:
Unknown status
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
In a related study, the investigators have found evidence that patients with Barrett's
esophagus have a leak for oral sucrose to leave their upper gastrointestinal tract, enter the
blood, and be filtered into urine. The amount of sucrose appearing in an overnight urine
sample can be used to indicate the presence of Barrett's esophagus and/or esophagitis in a
patient reporting with reflux (GERD) symptoms. The leak is presumably in the Barrett's
epithelium itself. This phenomenon will be used to test if a standard 8 week therapy of
Nexium in a first-time-presenting GERD patient can reduce the leak as a means of assessing
the efficacy of the drug in that patient. The investigators predict that Nexium will reduce
leak in esophagitis but not Barrett's patients.
Phase:
Phase 1
Details
Lead Sponsor:
Main Line Health
Collaborators:
AstraZeneca Cancer Research Foundation of America Sharpe-Strumia Research Foundation